clinical trial · NCT06852222
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Janssen Research & Development, LLC·phase3·recruiting·n = 600
Leukemia, Myeloid, AcuteBleximenibVenetoclax (VEN)Azacitidine (AZA)Placebo
brief summary
The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with newly diagnosed Acute Myeloid Leukemia (AML) with a mutation in the NPM1 or KMT2A gene.
started
Jun 4, 2025
primary completion
Jun 22, 2029
completion
Aug 15, 2029
last updated
May 8, 2026
official title
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations Who Are Ineligible for Intensive Chemotherapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol